-
9m 52sPart 1 | Session 3 Clinical Implications of the STRIDE Study for Endocrinologists
-
13m 50s
-
7m 12sPart 1 | Session 5 Efficacy and Safety of CagriSema in REDEFINE 1 and 2
-
4m 46sPart 1 | Session 1 PATHWEIGH: Weight Management in Primary Care
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.
We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once-monthly MariTide for the treatment of obesity in patients with or without type 2 diabetes. The primary outcome measure was the percent change in body weight from baseline to week 52.
Findings suggest MariTide was efficacious, with sustained weight loss without plateau observed at 52 weeks. Patients with both type 2 diabetes and obesity also had improvements in HbA1c.
Interview Questions:
- Could you tell us about the mechanism of action behind MariTide and the importance behind the study?
- What was the study design and patient population?
- What were the key findings and how can they be used to identify patients who would benefit most from MariTide?
- What are the take-home messages for practice?
- What further research is needed in this area?
Recorded remotely from Louisville, 2025.
Editors: Yazmin Sadik, Jordan Rance
Videographer: Tom Green
Support: This is an independent interview produced by Radcliffe CVRM.
Watch Expert Interviews sharing the late-breaking trial data from the American Diabetes Association's Scientific Sessions 2025.
More from this programme
Part 1
Expert Interviews
Faculty Biographies
Harold Bays
Medical Director and President
Dr Harold Bays is Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center, US. He has served as a Principal Investigator for over 600 clinical trials of metabolic therapeutic interventions.
Dr Bays is Board Certified in Internal Medicine and Endocrinology and Metabolism, Diplomate of the American Board of Obesity Medicine, and a Diplomate of the American Board of Clinical Lipidology. He is a Fellow of the Obesity Medicine Association, The Obesity Society, the American College of Cardiology, the American Association of Clinical Endocrinologists, the National Lipid Association, and the American Society of Preventive Cardiology.
Dr Bays has written or served as a contributing author to over 350 scientific manuscripts and book chapters and authored/presented 100’s of scientific abstracts.
Comments